Beijing Dacheng Law Firm
Legal Opinion on Shanxi Zhendong Pharmaceutical Co., Ltd.'s 2026 First Extraordinary General Meeting
To: Shanxi Zhendong Pharmaceutical Co., Ltd.
In accordance with the "Company Law of the People's Republic of China" (hereinafter referred to as the "Company Law"), the "Securities Law of the People's Republic of China" (hereinafter referred to as the "Securities Law"), and the "Rules for Shareholders' Meetings of Listed Companies (2025 Revision)" (hereinafter referred to as the "Shareholders' Meeting Rules") issued by the China Securities Regulatory Commission, as well as other relevant laws, regulations, and normative documents, Beijing Dacheng Law Firm (hereinafter referred to as "the Firm") has been entrusted by Shanxi Zhendong Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") to send lawyers to attend the Company's 2026 First Extraordinary General Meeting (hereinafter referred to as the "Meeting").
The Firm hereby declares: The Firm's lawyers will only express legal opinions on the convening procedures, meeting procedures, attendee qualifications, convener qualifications, voting procedures, and voting results of this Meeting. The Firm will not express opinions on the proposals discussed at this Meeting, nor on the numbers or content of the matters involved in the proposals. The Firm's lawyers agree to include this Legal Opinion along with other information disclosure materials for this Meeting for public announcement.
This Legal Opinion is solely for the purpose of verifying the legality of matters related to the Company's Meeting and shall not be used for any other purpose.
The Firm and the handling lawyers, in accordance with the "Securities Law," the "Administrative Measures for Securities Legal Business of Law Firms," and the "Practice Rules for Securities Legal Business of Law Firms (Trial)," as well as facts that have occurred or exist prior to the issuance of this Legal Opinion, have strictly performed their statutory duties, adhered to the principles of diligence and good faith, conducted thorough investigations and verifications, and ensured that the facts identified in this Legal Opinion are true, accurate, and complete, and that the conclusions expressed are legal and accurate, without any false records, misleading statements, or significant omissions, and shall bear corresponding legal responsibilities.
In accordance with Article 6 of the "Shareholders' Meeting Rules," the Firm's lawyers, adhering to the generally accepted professional standards, ethical norms, and the spirit of diligence and responsibility of the legal profession, have conducted necessary investigations and verifications of the matters and relevant documents related to this Meeting, attended this Meeting, and hereby issue the following legal opinion:
I. Procedures for Convening and Holding the Meeting
(I) Convening Procedures for the Meeting
The Meeting was proposed and convened by the Company's Board of Directors. On April 8, 2026, the Company held the twelfth meeting of the sixth session of the Board of Directors, which deliberated and approved the "Proposal on Convening the 2026 First Extraordinary General Meeting." On April 9, 2026, the Company announced the "Notice of Shanxi Zhendong Pharmaceutical Co., Ltd. on Convening the 2026 First Extraordinary General Meeting" (hereinafter referred to as the "Notice of the Meeting") on the official website of the Shenzhen Stock Exchange and the Juchao Information Network.
The "Notice of the Meeting" specified the date, time, location, voting methods, online voting times, share registration date, and meeting registration methods for the Meeting, and stated that shareholders registered with the Company or their authorized representatives could attend the Meeting, and also listed the matters to be discussed at the Meeting.
(II) Meeting Procedures
The Meeting was held through a combination of on-site voting and online voting.
The Meeting commenced at 9:00 AM on April 24, 2026, in the conference room on the 4th floor of Zhendong Technology Building, No. 18 Chuangye Road, Haidian District, Beijing, and was presided over by Mr. Li Kun, Chairman of the Company.